Scholarlink

<p>Radiotherapy is a mainstay of cancer treatment, yet its efficacy is still substantially restricted due to radioresistance. The mechanisms underlying radioresistance remain elusive, impeding drug development and therapeutics. Here, using a high-throughput random gene perturbation method based on <i>piggyBac</i> transposon, we screened and identified CABLES1, an adaptor protein, as a key regulator of tumor radioresistance. The function of CABLES1 in radioresistance was further validated in multiple human cell lines in vitro and a mouse xenograft model in vivo. High expression of CABLES1 is significantly correlated with radioresistance in cancer patients. Mechanistically, CABLES1 interacts with XRCC6/XRCC5 heterodimer and activates DNA-PKcs by promoting DNA-PK holoenzyme formation, thus facilitating the efficiency of nonhomologous end-joining (NHEJ) repair and radioresistance. Notably, YTHDF1 recognizes METTL14-deposited m<sup>6</sup>A modification on <i>CABLES1</i> mRNA to enhance its translation in response to ionizing radiation (IR), thereby sustaining the elevation of NHEJ repair capacity and radioresistance. Through high-throughput screening of a small molecule library, we showed that theaflavin 3,3’-digallate (TF-3) specifically disrupts the CABLES1-XRCC6 interaction, thereby sensitizing cancer cells to radiotherapy. Together, our study unveils the molecular mechanism by which CABLES1 potentiates tumor radioresistance, providing a novel synthetic lethal strategy for targeting cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

m6A-mediated CABLES1 translation potentiates tumor radioresistance via facilitating nonhomologous end-joining repair

  • 期刊论文

  • 发表日期：

    2026年5月9日

查看全文
  • Changzhi Li,
  • Xianchao Tang,
  • Zimi Zeng,
  • Liqian Yang,
  • Fang Cao,
  • Haiyan Zhu,
  • Liqing Zhu,
  • Jie Shen,
  • Xiaocui Bian,
  • Libin Wang,
  • Yang Liu,
  • Fengbiao Mao,
  • De Chang,
  • Pengtao Jiao,
  • Haiying Wang,
  • Kailong Li

摘要

Radiotherapy is a mainstay of cancer treatment, yet its efficacy is still substantially restricted due to radioresistance. The mechanisms underlying radioresistance remain elusive, impeding drug development and therapeutics. Here, using a high-throughput random gene perturbation method based on piggyBac transposon, we screened and identified CABLES1, an adaptor protein, as a key regulator of tumor radioresistance. The function of CABLES1 in radioresistance was further validated in multiple human cell lines in vitro and a mouse xenograft model in vivo. High expression of CABLES1 is significantly correlated with radioresistance in cancer patients. Mechanistically, CABLES1 interacts with XRCC6/XRCC5 heterodimer and activates DNA-PKcs by promoting DNA-PK holoenzyme formation, thus facilitating the efficiency of nonhomologous end-joining (NHEJ) repair and radioresistance. Notably, YTHDF1 recognizes METTL14-deposited m6A modification on CABLES1 mRNA to enhance its translation in response to ionizing radiation (IR), thereby sustaining the elevation of NHEJ repair capacity and radioresistance. Through high-throughput screening of a small molecule library, we showed that theaflavin 3,3’-digallate (TF-3) specifically disrupts the CABLES1-XRCC6 interaction, thereby sensitizing cancer cells to radiotherapy. Together, our study unveils the molecular mechanism by which CABLES1 potentiates tumor radioresistance, providing a novel synthetic lethal strategy for targeting cancer.